
    
      This study is a modified and expanded protocol based on acceptable safety results from an
      earlier feasibility study. The trial is conducted using a 3:1 randomization (treatment to
      control) in which patients are screened for eligibility, randomized at time of surgery and
      followed for 24 months postoperatively.
    
  